Compare HLLY & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLLY | LCTX |
|---|---|---|
| Founded | 1903 | 1990 |
| Country | United States | United States |
| Employees | 1483 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.9M | 301.7M |
| IPO Year | N/A | 1996 |
| Metric | HLLY | LCTX |
|---|---|---|
| Price | $2.38 | $1.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.83 | ★ $6.25 |
| AVG Volume (30 Days) | 858.5K | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $6.32 | $109.40 |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $1.98 | $0.93 |
| 52 Week High | $4.48 | $2.09 |
| Indicator | HLLY | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 56.41 |
| Support Level | N/A | N/A |
| Resistance Level | $2.65 | $1.80 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 21.88 | 82.41 |
Holley Inc designs, manufactures, and distributes high-performance automotive aftermarket products to car and truck enthusiasts in the United States, Canada and Europe. It manufactures a diversified line of performance automotive products, including carburetors, fuel pumps, fuel injection systems, nitrous oxide injection systems, superchargers, exhaust headers, mufflers, distributors, ignition components, engine tuners and automotive performance plumbing products. It also manufactures exhaust products as well as shifters, converters, transmission kits, transmissions, tuners and automotive software. The company markets its products under brands such as Holley, Holley EFI, MSD, Simpson, Flowmaster, EDGE, Cataclean, and Accel, among others. It operates in single segment.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.